Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing cabozantinib with or without nivolumab versus standard chemotherapy in patients with non-squamous non-small cell lung cancer. The FDA has approved the use of Arm B (cabozantinib S-malate, nivolumab) to treat patients with Lung Cancer. This is the first time that this combination of drugs has been approved to treat this particular condition. Patients in this trial will not receive a placebo.
Eligible Conditions
- Lung Cancer
- Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
- Stage IIIC Lung Cancer AJCC v8
- Lung
- Stage IVA Lung Cancer AJCC v8
- Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
- Malignant Neoplasms
- Stage IIIB Lung Cancer AJCC v8
Treatment Effectiveness
Effectiveness Progress
Other trials for Lung Cancer
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Every 6 weeks for the first year on study, and then every 12 weeks after year one
After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
Progression-free survival (PFS) for patient population with non-squamous no-small cell lung cancer (NSCLC)
After the completion of study treatment
Agreement between central view and site review in terms of progression-free survival
Correlative biomarker research
Week 12
Best objective response for each arm
The RECIST1.1 response at each time point
Year 3
Overall survival (OS) for each arm
Year 3
Toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Lung Cancer
Trial Design
3 Treatment Groups
Arm C (standard chemotherapy,cabozantinib S-malate, nivolumab)
1 of 3
Arm B (cabozantinib S-malate, nivolumab)
1 of 3
Arm A (cabozantinib S-malate)
1 of 3
Active Control
Experimental Treatment
142 Total Participants · 3 Treatment Groups
Primary Treatment: Cabozantinib S-malate · No Placebo Group · Phase 2
Arm B (cabozantinib S-malate, nivolumab)Experimental Group · 2 Interventions: Cabozantinib S-malate, Nivolumab · Intervention Types: Drug, Biological
Arm A (cabozantinib S-malate)
Drug
Experimental Group · 1 Intervention: Cabozantinib S-malate · Intervention Types: DrugArm C (standard chemotherapy,cabozantinib S-malate, nivolumab)ActiveComparator Group · 7 Interventions: Cabozantinib S-malate, Nab-paclitaxel, Paclitaxel, Ramucirumab, Docetaxel, Gemcitabine Hydrochloride, Nivolumab · Intervention Types: Drug, Drug, Drug, Biological, Drug, Drug, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
FDA approved
Nivolumab
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: every 6 weeks for the first year on study, and then every 12 weeks after year one
Closest Location: Advocate Illinois Masonic Medical Center · Chicago, IL
2009First Recorded Clinical Trial
0 TrialsResearching Lung Cancer
10 CompletedClinical Trials
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
12,930 Previous Clinical Trials
41,293,645 Total Patients Enrolled
Joel W NealPrincipal InvestigatorECOG-ACRIN Cancer Research Group
2 Previous Clinical Trials
128 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have MET exon 14 splice mutations on DNA analysis.
You are eligible for this study if you have tumors with known molecular alterations in ROS1, MET, RET, or must have progressed radiographically (per local investigator assessment) following one, but only one, line of platinum-based chemotherapy AND one, but only one, line of prior immunotherapy
Patient must have stage IV disease (includes M1a, M1b, or recurrent earlier stage disease), according to the 8th edition of the lung cancer Tumor Node Metastasis (TNM) classification system.
Patient must have predominant non-squamous histology (patients with NSCLC no otherwise specified [NOS] are eligible)
You have a mutation in MET and you are eligible for this trial.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments